{"id":"NCT00334958","sponsor":"Eisai Inc.","briefTitle":"Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures","officialTitle":"A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02-13","primaryCompletion":"2009-05-20","completion":"2009-05-20","firstPosted":"2006-06-08","resultsPosted":"2013-02-05","lastUpdate":"2021-06-14"},"enrollment":356,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Rufinamide","otherNames":["E2080","BANZEL"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Rufinamide","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).","primaryOutcome":{"measure":"Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase","timeFrame":"Baseline, Days 13 to 96","effectByArm":[{"arm":"Rufinamide","deltaMin":-23.25,"sd":null},{"arm":"Placebo","deltaMin":-9.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":77,"countries":["United States"]},"refs":{"pmids":["33179247"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":176},"commonTop":["Dizziness","Headache","Fatigue","Somnolence","Nausea"]}}